Peginterferon alfa-2a
Clinical data | |
---|---|
Trade names | Pegasys, others |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a605029 |
License data | |
Pregnancy category |
|
Subcutaneous injection | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number |
|
DrugBank | |
ChemSpider |
|
UNII |
|
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C860H1353N227O255S9 |
Molar mass | 19241.16 g·mol−1 |
(what is this?) (verify) |
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat
Side effects are common.
Pegylated interferon alfa-2a was approved for medical use in the United States in 2002.[2] It is on the World Health Organization's List of Essential Medicines.[6]
Medical uses
This drug is approved around the world for the treatment of chronic hepatitis C (including people with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B. It is also used in the treatment of certain T-cell lymphomas, particularly mycosis fungoides.[citation needed]
Peginterferon alfa-2a is a long acting interferon. Interferons are
Host genetic factors
For genotype 1 hepatitis C treated with pegylated interferon alfa-2a or pegylated interferon alfa-2b combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature,[8] showed genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. Another report in Nature demonstrated the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.[9]
Manufacturing
It is
Society and culture
Availability
Peginterferon alfa-2a is manufactured under the brand name Pegasys. In 2021,
Research
A Cochrane Review sought to determine whether interferon alfa-2a could be used as a treatment for individuals with neovascular age-related macular degeneration. They found no evidence of improved visual acuity with potential harm.[17]
References
- FDA. Retrieved 22 October 2023.
- ^ a b c d e f g h "Peginterferon Alfa-2a (Professional Patient Advice) - Drugs.com". www.drugs.com. Archived from the original on 16 January 2017. Retrieved 12 January 2017.
- ^ "Pegasys 135 mcg and 180 mcg solution for injection in pre-filled pen - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Archived from the original on 13 January 2017. Retrieved 12 January 2017.
- ISBN 9780857111562.
- ^ a b "Peginterferon alfa-2a (Pegasys) - Treatment - Hepatitis C Online". www.hepatitisc.uw.edu. Archived from the original on 23 December 2016. Retrieved 12 January 2017.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Interferon alfa-2a Uses, Side Effects & Warnings". Drugs.com. Retrieved 10 January 2020.
- S2CID 1707096.
- PMID 19759533.
- PMID 12052715.
- ^ "Pegasys (peginterferon alfa-2a)". Genentech. Archived from the original on 8 January 2023. Retrieved 8 January 2023.
- ^ "Verzichtserklärung der Zulassung - Mittelfristig läuft Pegasys aus" (PDF). www.roche.de (German). Archived from the original (PDF) on 4 December 2021. Retrieved 4 December 2021.
- ^ "Pegasys (Peginterferon alfa-2a) langfristig weiterhin erhältlich" (PDF). Roche (in German). Archived from the original (PDF) on 4 December 2021. Retrieved 4 December 2021.
- ^ "pharma& portfolio". zr pharma& GmbH. Retrieved 4 December 2021.
- ^ "HALF-YEAR REPORT 2021, p.20" (PDF). Roche. Archived from the original (PDF) on 24 November 2021. Retrieved 4 December 2021.
- ^ "Pegasys". Roche Australia. Retrieved 8 January 2023.
- PMID 16437522.
External links
- Pegasys at the U.S. National Library of Medicine Medical Subject Headings (MeSH)